{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:30:59Z","timestamp":1793255459318,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite a well-established association of CYP3A5 genotype with tacrolimus dose requirements and clinical practice guidelines for personalized dosing, integration of genotype-guided tacrolimus dosing is limited. Herein we describe the process for implementing a CYP3A5 genotype\u2013guided tacrolimus dosing protocol in adult kidney transplant recipients at an academic medical center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We evaluated existing primary literature and clinical practice guidelines, as well as internal data, to determine the target population for implementation. Adult kidney transplant recipients were selected given the routine use of oral tacrolimus and limited drug-drug interactions. These data were also used to gain prescriber buy-in for and determine genotype-guided tacrolimus dose recommendations. Selecting a testing laboratory involved assessment of variant coverage, turnaround time, cost, and the return process for results. Obtaining testing before transplantation required development of multiple workflows to capture patients at listing or on the waitlist and for in-person and virtual care. Clinical decision support to automatically select initial post-transplantation tacrolimus doses per the genotype-guided protocol was developed. Clinician education was tailored to the role the individual had in the implementation process, and patient education was developed. Genotype-guided dosing was implemented in October 2023, approximately 1 year after conceptualization. The majority (61%) of adult kidney transplant recipients since implementation have received genotype-guided dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Implementation of CYP3A5 genotype\u2013guided tacrolimus dosing requires unique considerations associated with route of administration and transplant population, but integrating pharmacogenetics into a tacrolimus dosing protocol is feasible with multidisciplinary support. Future studies will evaluate the impact of this dosing strategy on clinical and healthcare utilization outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf215","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T11:51:08Z","timestamp":1755258668000},"page":"e134-e141","source":"Crossref","is-referenced-by-count":7,"title":["Establishing a\n                    <i>CYP3A5<\/i>\n                    genotype\u2013guided tacrolimus dosing protocol in adult kidney transplant recipients"],"prefix":"10.1093","volume":"83","author":[{"given":"Amy L","family":"Pasternak","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, MI"},{"name":"Department of Pharmacy, University of Michigan Health System , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Health Information and Technology Services, University of Michigan Health System , Ann Arbor, MI"},{"name":"Department of Pharmacy, University of Michigan Health System , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong M","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, MI"},{"name":"Department of Pharmacy, University of Michigan Health System , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"2S1","key":"2026012711371455300_zxaf215-B1","doi-asserted-by":"publisher","first-page":"S394","DOI":"10.1016\/j.ajt.2024.01.017","article-title":"OPTN\/SRTR 2022 annual data report: lung","volume":"24","author":"Valapour","year":"2024","journal-title":"Am J Transplant"},{"issue":"2S1","key":"2026012711371455300_zxaf215-B2","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1016\/j.ajt.2024.01.016","article-title":"OPTN\/SRTR 2022 annual data report: heart","volume":"24","author":"Colvin","year":"2024","journal-title":"Am J Transplant"},{"issue":"2S1","key":"2026012711371455300_zxaf215-B3","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.ajt.2024.01.012","article-title":"OPTN\/SRTR 2022 annual data report: kidney","volume":"24","author":"Lentine","year":"2024","journal-title":"Am J Transplant"},{"issue":"3","key":"2026012711371455300_zxaf215-B4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2026012711371455300_zxaf215-B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2026012711371455300_zxaf215-B6","author":"Food and Drug Administration"},{"issue":"10","key":"2026012711371455300_zxaf215-B7","doi-asserted-by":"publisher","first-page":"e14037","DOI":"10.1111\/ctr.14037","article-title":"National survey of physicians\u2019 perspectives on pharmacogenetic testing in solid organ transplantation","volume":"34","author":"Deininger","year":"2020","journal-title":"Clin Transplant"},{"issue":"6","key":"2026012711371455300_zxaf215-B8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/clpt.2010.17","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"2026012711371455300_zxaf215-B9","doi-asserted-by":"publisher","first-page":"e13285","DOI":"10.1111\/petr.13285","article-title":"A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation","volume":"22","author":"Min","year":"2018","journal-title":"Pediatr Transplant"},{"issue":"8","key":"2026012711371455300_zxaf215-B10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/phar.2601","article-title":"Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients","volume":"41","author":"Leino","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2026012711371455300_zxaf215-B11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/PGPM.S285444","article-title":"Evaluating the impact of CYP3A5 genotype on post-transplant healthcare resource utilization in pediatric renal and heart transplant recipients receiving tacrolimus","volume":"14","author":"Pasternak","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"issue":"1","key":"2026012711371455300_zxaf215-B12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11096-018-0750-5","article-title":"Effect of CYP3A5 genotype on hospitalization cost for kidney transplantation","volume":"41","author":"Vannaprasaht","year":"2019","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"2026012711371455300_zxaf215-B13","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1111\/ajt.13788","article-title":"Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype","volume":"16","author":"Pallet","year":"2016","journal-title":"Am J Transplant"},{"issue":"7","key":"2026012711371455300_zxaf215-B14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation","volume":"16","author":"Shuker","year":"2016","journal-title":"Am J Transplant"},{"issue":"9","key":"2026012711371455300_zxaf215-B15","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/bcp.13980","article-title":"Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients","volume":"85","author":"Anutrakulchai","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2026012711371455300_zxaf215-B16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/jac5.1699","article-title":"How to implement a pharmacogenetics service at your institution","volume":"5","author":"Cicali","year":"2022","journal-title":"J Am Coll Clin Pharm"},{"issue":"1","key":"2026012711371455300_zxaf215-B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpt.2387","article-title":"Pharmacogenomic clinical decision support: a review, how-to guide, and future vision","volume":"112","author":"Wake","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2026012711371455300_zxaf215-B18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jac5.1118","article-title":"Precision pharmacotherapy: integrating pharmacogenomics into clinical pharmacy practice","volume":"2","author":"Hicks","year":"2019","journal-title":"J Am Coll Clin Pharm"},{"issue":"4","key":"2026012711371455300_zxaf215-B19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/jpm10040154","article-title":"Establishment of a pharmacogenetics service focused on optimizing existing pharmacogenetic testing at a large academic health center","volume":"10","author":"Pasternak","year":"2020","journal-title":"J Pers Med"},{"key":"2026012711371455300_zxaf215-B20","author":"Scientific Registry of Transplant Recipients"},{"key":"2026012711371455300_zxaf215-B21","author":"BMT INFONET"},{"issue":"12","key":"2026012711371455300_zxaf215-B22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2165\/00003088-200544120-00010","article-title":"Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies","volume":"44","author":"Saint-Marcoux","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2026012711371455300_zxaf215-B23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2217\/pgs-2018-0003","article-title":"CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration","volume":"19","author":"Pasternak","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"6","key":"2026012711371455300_zxaf215-B24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/10600280231197399","article-title":"CYP3A5 genotype-dependent drug-drug interaction between tacrolimus and voriconazole in Chinese kidney transplant patients","volume":"58","author":"Zhang","year":"2024","journal-title":"Ann Pharmacother"},{"key":"2026012711371455300_zxaf215-B25","doi-asserted-by":"publisher","first-page":"692922","DOI":"10.3389\/fphar.2021.692922","article-title":"CYP3A5 genotype-dependent drug-drug interaction between tacrolimus and nifedipine in Chinese renal transplant patients","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"2026012711371455300_zxaf215-B26","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1111\/ajt.14232","article-title":"Determinants of the magnitude of interaction between tacrolimus and voriconazole\/posaconazole in solid organ recipients","volume":"17","author":"Vanhove","year":"2017","journal-title":"Am J Transplant"},{"issue":"6","key":"2026012711371455300_zxaf215-B27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/FPC.0b013e32832bd085","article-title":"CYP3A5*1\/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole","volume":"19","author":"Chandel","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"2026012711371455300_zxaf215-B28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/FPC.0b013e328307c26e","article-title":"Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients","volume":"18","author":"Kuypers","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"2026012711371455300_zxaf215-B29","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.15.21267864","article-title":"The Michigan Genomics Initiative: a biobank linking genotypes and electronic clinical records in Michigan Medicine patients","author":"Zawistowski","journal-title":"medRxiv"},{"key":"2026012711371455300_zxaf215-B30","author":"Envarsus"},{"issue":"3","key":"2026012711371455300_zxaf215-B31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jac5.1118","article-title":"Precision pharmacotherapy: integrating pharmacogenomics into clinical pharmacy practice","volume":"2","author":"Hicks","year":"2019","journal-title":"J Am Coll Clin Pharm"},{"issue":"9","key":"2026012711371455300_zxaf215-B32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","article-title":"CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase","volume":"25","author":"Pratt","year":"2023","journal-title":"J Mol Diagn"},{"issue":"8","key":"2026012711371455300_zxaf215-B33","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/jcph.2249","article-title":"Implementation of clinical cytochrome P450 3A genotyping for tacrolimus dosing in a large kidney transplant program","volume":"63","author":"Tillman","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2026012711371455300_zxaf215-B34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2217\/pgs-2020-0181","article-title":"Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs","volume":"22","author":"Luczak","year":"2021","journal-title":"Pharmacogenomics"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf215\/64075502\/zxaf215.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/3\/e134\/64075502\/zxaf215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/3\/e134\/64075502\/zxaf215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:37:21Z","timestamp":1769531841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/3\/e134\/8237253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,18]]},"published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf215","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,1]]},"published":{"date-parts":[[2025,8,18]]}}}